Abstract
High-dose therapy with the rescue of autologous stem cells represents today the standard approach for multiple myeloma patients aged < 65 years. Several studies, in fact, have demonstrated the superiority of high-dose therapy with respect to conventional chemotherapy in younger patients. Peripheral blood stem cells (PBSCs) provide a rapid and effective hematopoietic recovery after the administration of supra maximal chemotherapy and mainly for this reason have become the preferred source of stem cells for autologous transplantation. Recently, however, a number of new drugs have appeared in the armamentarium of the hematologist. Among these, thalidomide has been the first antiangiogenetic drug effectively adopted firstly in refractory-relapsed patients and now also as first line treatment with better results respect to VAD or VAD-like regimens. Inhibitors of proteasome, such as bortezomib, and other immunomodulatory agents, such as lenalidomide, have been also studied more recently in myeloma patients. In particular, bortezomib has shown to be very effective as single agent or in combination with high-dose dexamethasone. In this review, we try to define the potential role of these new drugs, how and when they can be included in the therapeutic program designed for younger and older patients, and mostly if and how these new agents could jeopardize the central role of autologous stem cell transplantation in the treatment of multiple myeloma.
Keywords: Thalidomide, Lenalidomide, Bortezomib, Chemotherapy, Transplantation
Current Stem Cell Research & Therapy
Title: The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma:Is there Still a Role for PBSC Transplantation?
Volume: 2 Issue: 1
Author(s): Alessandro Corso and Marzia Varettoni
Affiliation:
Keywords: Thalidomide, Lenalidomide, Bortezomib, Chemotherapy, Transplantation
Abstract: High-dose therapy with the rescue of autologous stem cells represents today the standard approach for multiple myeloma patients aged < 65 years. Several studies, in fact, have demonstrated the superiority of high-dose therapy with respect to conventional chemotherapy in younger patients. Peripheral blood stem cells (PBSCs) provide a rapid and effective hematopoietic recovery after the administration of supra maximal chemotherapy and mainly for this reason have become the preferred source of stem cells for autologous transplantation. Recently, however, a number of new drugs have appeared in the armamentarium of the hematologist. Among these, thalidomide has been the first antiangiogenetic drug effectively adopted firstly in refractory-relapsed patients and now also as first line treatment with better results respect to VAD or VAD-like regimens. Inhibitors of proteasome, such as bortezomib, and other immunomodulatory agents, such as lenalidomide, have been also studied more recently in myeloma patients. In particular, bortezomib has shown to be very effective as single agent or in combination with high-dose dexamethasone. In this review, we try to define the potential role of these new drugs, how and when they can be included in the therapeutic program designed for younger and older patients, and mostly if and how these new agents could jeopardize the central role of autologous stem cell transplantation in the treatment of multiple myeloma.
Export Options
About this article
Cite this article as:
Corso Alessandro and Varettoni Marzia, The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma:Is there Still a Role for PBSC Transplantation?, Current Stem Cell Research & Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488807779316955
DOI https://dx.doi.org/10.2174/157488807779316955 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets New Technologies in Male Contraception
Current Women`s Health Reviews Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Particulate Vaccine Dispersions Emerge as a Novel Carrier for Deep Pulmonary Immunization
Current Nanomedicine Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
Current Pharmacogenomics and Personalized Medicine B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
Current Pharmaceutical Biotechnology IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Current Molecular Medicine Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis